Max Planck spinout Quench Bio will wind down after its target proved undruggable and will return capital to investors, which include AbbVie Ventures.
Quench Bio, a US-based inflammatory disease drug developer exploiting research at several Max Planck institutes and Lead Discovery Center (LDC), announced yesterday that it was shutting down.
The spinout took the decision after its target proved undruggable. It will return capital to investors and, in due course, publish key findings into the gasdermin D protein – which plays a role in inflammatory diseases but the mechanisms of which are not yet fully understood.
Quench Bio also held an auction for…
